Form 4: Vaxcyte SVP of Finance, Elvia Cowan, Reports Stock Transactions

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., reports the acquisition and disposal of common stock and stock options.

Summary

• Elvia Cowan, the SVP of Finance at Vaxcyte, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On February 27, 2025, Cowan acquired 5,379 shares of common stock through restricted stock units (RSUs) at $0.
• On February 28, 2025, Cowan disposed of 242 shares of common stock at $73.02 to cover tax withholding obligations.
• On March 3, 2025, Cowan disposed of 325 shares of common stock at $72.10, also for tax withholding.
• Cowan also acquired 17,961 stock options with an exercise price of $74.22, vesting monthly starting March 27, 2025, and expiring on February 26, 2035.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions by a company insider, with no inherent positive or negative implications.

Future Outlook

The RSUs vest as to 25% of the shares subject to the award on September 7, 2025 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. 1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they represent routine insider trading activity.

Key Dates